KZIA is Kazia Therapeutics Limited (Healthcare) — a non-dividend-paying stock. Trading at $12.61. Market cap: $196M.
Stock snapshot
| Price | $12.61 |
| Market cap | $196M |
| Sector | Healthcare |
| Exchange | NCM |
| Pays dividend | No |
About KZIA
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Related non-dividend companies
Other non-dividend stocks investors research alongside KZIA. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is KZIA's current stock price?
KZIA (Kazia Therapeutics Limited) is currently trading at $12.61.
Does KZIA pay a dividend?
KZIA (Kazia Therapeutics Limited) does not currently pay a regular dividend.
Track KZIA in DiviDrip
Add KZIA to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search KZIA and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-03. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.